Art. -Nr.: HY-N0587

Demethylzeylasteral

6 Cited Publications

Kundenbewertung

Based on 6 publication(s) in Google Scholar

Demethylzeylasteral is an orally active triterpenoid compound isolated from Tripterygium wilfordii, which has functions such as anti-inflammatory, anti-tumor, anti fertility, estrogen metabolism regulation, immune suppression, and immune system regulation ^[1][2].

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.92%
CAS. Nr.: 107316-88-1
Formel: C₂₉H₃₆O₆
Molecular Weight:480.59

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Demethylzeylasteral Chemical Structure

CAS. Nr.: 107316-88-1

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (6)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Alle TGF-beta/Smad Isoform-spezifische Produkte anzeigen :

Smad1
Smad3

Alle Estrogen Receptor/ERR Isoform-spezifische Produkte anzeigen :

Alle NF-κB Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
A2780	IC₅₀	10.11 μM Compound: Demethylzeylasteral	Cytotoxicity against human A2780 cells assessed as cell viability measured after 48 hrs by MTT assay Cytotoxicity against human A2780 cells assessed as cell viability measured after 48 hrs by MTT assay	[PMID: 38964974]

In Vitro

Demethylzeylasteral (0-50 μM, 72 h) inhibits cell growth and proliferation by inducing cell cycle arrest in glioma cells^[1].
Demethylzeylasteral (5, 10 μM, 48 h) inhibits matrix degradation, migration and invasion of breast cancer cells^[2].
Demethylzeylasteral (1-20 μM, 48 h) inhibits cell proliferation and induces apoptosis by inhibiting MCL1 in melanoma cells^[3].
Demethylzeylasteral (0-2 μM, 48 h) inhibits the proliferation, migration, and activation of hepatic stellate cells^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[1].

Cell Line:

LN-229, U-87, A-172, U-251 and U-118 cells
Concentration:

0-50 μM
Incubation Time:

72 h
Result:

Inhibited the proliferation rate of cells

Cell Migration Assay ^[2].

Cell Line:

MDA-MB-231 cell
Concentration:

5, 10 μM
Incubation Time:

48 h
Result:

Inhibited cell migration of MDA-MB-231 cells

Western Blot Analysis^[3].

Cell Line:

MV3 cell, A375 cell
Concentration:

1-20 μM
Incubation Time:

48 h
Result:

Reduced expression of anti-apoptotic protein MCL1

Western Blot Analysis^[6].

Cell Line:

LX-2 cell, HSC-T6 cell, primary HSC cell
Concentration:

0-2 μM
Incubation Time:

48 h
Result:

Reduced the mRNA and protein expression of COL1A1, MMP2, α-SMA, and TIMP-2

In Vivo

Demethylzeylasteral (30 mg/kg, 6 times every 2 days, i.p.) inhibits glioma growth by regulating the miR-30e-5p/MYBL2 axis^[1].
Demethylzeylasteral (4 mg/kg, 5 weeks, i.p.) inhibits the invasion of triple negative breast cancer by blocking classical and non classical TGF - β signaling pathways^[2].
Demethylzeylasteral (30-120 mg/kg, 8 weeks, i.p.) improves inflammation in a unilateral ureteral obstruction rat model by inhibiting the activation of the NF - κ B pathway^[4].
Demethylzeylasteral (10, 40 mg/kg, 30 days, i.g.) can alleviate atherosclerosis in AS rabbits^[5].
Demethylzeylasteral (10, 20 mg/kg, 4 weeks, p.o.) improves CCl4 induced liver fibrosis in mice by inhibiting AGAP2 mediated FAK/AKT signaling^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Female nude mice modeled with glioma LN-229 cells^[1].
Dosage:

30 mg/kg, 6 times every 2 days
Administration:

Intraperitoneal injection (i.p.)
Result:

Reduced tumor volume

Animal Model:

Female BALB/c mice modeled with 4T1 cells^[2].
Dosage:

4 mg/kg, 5 weeks
Administration:

Intraperitoneal injection (i.p.)
Result:

Reduced cancer lung metastasis

Animal Model:

Rat model of unilateral ureteral obstruction^[4].
Dosage:

30-120 mg/kg, 8 weeks
Administration:

Intraperitoneal injection (i.p.)
Result:

Inhibited the increases in serum creatinine, blood urea nitrogen and Up/Ucr ratio

Animal Model:

Atherosclerotic rabbit^[5].
Dosage:

10, 40 mg/kg, 30 days
Administration:

Intragastrical (i.g.)
Result:

Reduced blood lipids triglycerides (TG), total cholesterol (TC), low-density lipoprotein (LDL-C)

Animal Model:

CCl4-induced liver fibrosis model^[6].
Dosage:

10, 20 mg/kg, 4 weeks
Administration:

Oral gavage (p.o.)
Result:

Inhibited the expression of TGF-β1

Chemical Information

CAS. Nr. 107316-88-1
Appearance Solid
Molecular Weight 480.59
Formel C₂₉H₃₆O₆
Color Light yellow to yellow
SMILES

C[C@](C1=CC2=O)(CC[C@]3(C)[C@@]4([H])C[C@@](C(O)=O)(C)CC3)[C@]4(CC[C@]1(C5=C2C(C=O)=C(O)C(O)=C5)C)C
Structure Classification
- Terpenoids
- Triterpenes
Initial Source
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (6)

All Histological Imaging/StainingCell Proliferation/Viability AssayWBCell Migration/Invasion AssayOthers

Sort by:

Journal Impact Factor

Phytomedicine

Demethylzeylasteral ameliorates podocyte damage in murine lupus by inhibiting inflammation and enhancing autophagy. [Abstract]

2024 Aug 15:134:155966. PMID: 39241387
Phytomedicine

Demethylzeylasteral attenuates hepatic stellate cell activation and liver fibrosis by inhibiting AGAP2 mediated signaling. [Abstract]

2022 Oct:105:154349. PMID: 35905567
Cell Rep

Carvedilol sensitizes chemotherapy by targeting STING to boost anti-tumor immunity. [Abstract]

2025 Apr 16;44(5):115572. PMID: 40249703
J Ethnopharmacol

Demethylzeylasteral protects against renal interstitial fibrosis by attenuating mitochondrial complex I-mediated oxidative stress. [Abstract]

2024 Jun 12:327:117986. PMID: 38437887

Demethylzeylasteral purchased from MedChemExpress. Usage Cited in: J Ethnopharmacol. 2024 Jun 12:327:117986. [Abstract]

Demethylzeylasteral (DML: 10/20 mg/kg). Reduced kidney damage and fibrosis in UUO mice. Representative images stained with PAS, Sirius red, and Masson's red.

Demethylzeylasteral purchased from MedChemExpress. Usage Cited in: J Ethnopharmacol. 2024 Jun 12:327:117986. [Abstract]

Demethylzeylasteral (DML: 10/20 mg/kg) inhibited the expression of fibrosis-related proteins in UUO mice. The expression levels of α-SMA, FN, type I collagen, and TGF-β1 were also affected.

Demethylzeylasteral purchased from MedChemExpress. Usage Cited in: J Ethnopharmacol. 2024 Jun 12:327:117986. [Abstract]

Demethylzeylasteral (DML: 10/20 mg/kg) inhibits MitROS production and improves mitochondrial function. Total ROS concentration in kidney tissue.
J Bone Oncol

Demethylzeylasteral inhibits proliferation and metastasis of osteosarcoma cells by modulating the PI3K/AKT/Autophagy pathways. [Abstract]

2025 Jun 20:53:100699. PMID: 40655907

Demethylzeylasteral purchased from MedChemExpress. Usage Cited in: J Bone Oncol. 2025 Jun 20:53:100699. [Abstract]

Viability of MG63 cells treated with varying concentrations of DEM (Demethylzeylasteral: 0, 10, 20, and 40 uM) for 24, 48, and 72 h, assessed using a CCK8 assay.

Demethylzeylasteral purchased from MedChemExpress. Usage Cited in: J Bone Oncol. 2025 Jun 20:53:100699. [Abstract]

Transwell migration assays assessed the migration ability of 143B and MG63 cells after treatment with DMSO or DEM (Demethylzeylasteral: 0, 10, 20, and 40 μM) for 48 hours.
Toxicol Appl Pharmacol

Demethylzeylasteral inhibits osteosarcoma cell proliferation by regulating METTL17-mediated mitochondrial oxidative phosphorylation. [Abstract]

2025 Apr 16:117348. PMID: 40250487

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 175 mg/mL (364.14 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.0808 mL

10.4039 mL

20.8078 mL

5 mM

0.4162 mL

2.0808 mL

4.1616 mL

10 mM

0.2081 mL

1.0404 mL

2.0808 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (4.33 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (289 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Zhang K, et al. Demethylzeylasteral inhibits glioma growth by regulating the miR-30e-5p/MYBL2 axis. Cell Death Dis. 2018 Oct 10;9(10):1035. [Content Brief]

[2]. Li L, et al. Demethylzeylasteral (T-96) inhibits triple-negative breast cancer invasion by blocking the canonical and non-canonical TGF-β signaling pathways. Naunyn Schmiedebergs Arch Pharmacol. 2019 May;392(5):593-603. [Content Brief]

[3]. Zhao Y, et al. Demethylzeylasteral inhibits cell proliferation and induces apoptosis through suppressing MCL1 in melanoma cells. Cell Death Dis. 2017 Oct 26;8(10):e3133. [Content Brief]

[4]. Wang Q, et al. Demethylzeylasteral ameliorates inflammation in a rat model of unilateral ureteral obstruction through inhibiting activation of the NF‑κB pathway. Mol Med Rep. 2017 Jul;16(1):373-379. [Content Brief]

[5]. Huang Y, et al. Experimental study of the anti-atherosclerotic effect of demethylzeylasteral. Exp Ther Med. 2017 Jun;13(6):2787-2792. [Content Brief]

[6]. Chen K, et al. Demethylzeylasteral attenuates hepatic stellate cell activation and liver fibrosis by inhibiting AGAP2 mediated signaling. Phytomedicine. 2022 Oct;105:154349. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.0808 mL	10.4039 mL	20.8078 mL	52.0194 mL
	5 mM	0.4162 mL	2.0808 mL	4.1616 mL	10.4039 mL
	10 mM	0.2081 mL	1.0404 mL	2.0808 mL	5.2019 mL
	15 mM	0.1387 mL	0.6936 mL	1.3872 mL	3.4680 mL
	20 mM	0.1040 mL	0.5202 mL	1.0404 mL	2.6010 mL
	25 mM	0.0832 mL	0.4162 mL	0.8323 mL	2.0808 mL
	30 mM	0.0694 mL	0.3468 mL	0.6936 mL	1.7340 mL
	40 mM	0.0520 mL	0.2601 mL	0.5202 mL	1.3005 mL
	50 mM	0.0416 mL	0.2081 mL	0.4162 mL	1.0404 mL
	60 mM	0.0347 mL	0.1734 mL	0.3468 mL	0.8670 mL
	80 mM	0.0260 mL	0.1300 mL	0.2601 mL	0.6502 mL
	100 mM	0.0208 mL	0.1040 mL	0.2081 mL	0.5202 mL

Keywords

Demethylzeylasteral

6 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Demethylzeylasteral

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

NF-κB Signaling Compound Library

Protein Tyrosine Kinase Compound Library

Stem Cell Signaling Compound Library

TGF-beta/Smad Compound Library

Wnt/Hedgehog/Notch Compound Library

Natural Product Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Covalent Screening Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Oxygen Sensing Compound Library

Anti-Cardiovascular Disease Compound Library

Endocrinology Compound Library

Terpenoids Library

Pyroptosis Compound Library

Cytoskeleton Compound Library

Orally Active Compound Library

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Anti-Cancer Natural Product Library

Antidepressant Compound Library

Plant-Sourced Natural Product Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Nuclear Receptor Compound Library

Osteogenesis Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Membrane Receptor-targeted Compound Library

Cell Death Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

Anti-Aging Compound Library Mini

Covalent Screening Library Plus

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Fibrosis Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Mass Spectrometry Human Metabolite Library

Posttranslational Modification Library

Natural Product Diversity Scaffold Library

RNA Binding Bioactive Compound Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Demethylzeylasteral

Alle TGF-beta/Smad Isoform-spezifische Produkte anzeigen

Alle Estrogen Receptor/ERR Isoform-spezifische Produkte anzeigen

Alle NF-κB Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (6)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Demethylzeylasteral Related Classifications

HY-N0587 Related Classifications